Anti-Lipoprotein Lipase Antibodies in Patients with Hypertriglyceridemia without Associated Autoimmune Disease

Carregando...
Imagem de Miniatura
Citações na Scopus
9
Tipo de produção
article
Data de publicação
2011
Título da Revista
ISSN da Revista
Título do Volume
Editora
ISRAEL MEDICAL ASSOC JOURNAL
Citação
ISRAEL MEDICAL ASSOCIATION JOURNAL, v.13, n.6, p.350-353, 2011
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
Background: Anti-lipoprotein lipase antibodies have been described in rare cases of patients with hypertriglyceridemia. However, no systematic study evaluating these antibodies in patients with this lipid abnormality has been undertaken. Objectives: To analyze the correlation of anti-lipoprotein lipase (anti-LPL) antibodies with other laboratory findings in patients with hypertriglyceridemia but no autoimmune disease. Methods: We evaluated 44 hypertriglyceridemic patients without autoimmune disease. Clinical and laboratory evaluations included analyses of comorbidities, fasting lipid profile and anti-LPL antibodies. Results: Mean patient age was 55 +/- 10 years; 46% of the patients were female and 64% were Caucasian. The mean disease duration was 94.4 months and mean body mass index 28.7 +/- 3.6 kg/m(2); 34.0% were diabetic, 25.0% were obese, 72.7% had systemic arterial hypertension, 75% were sedentary, 15.9% were smokers, 56.8% had a family history of dyslipidemia, 45.5% had a family history of coronary insufficiency, 20.5% had acute myocardial infarction, 9.0% had undergone revascularization and 11.0% angioplasty, 79.5% were being treated with statins and 43.2% were taking fibrates. Median triglyceride levels were 254 mg/dl (range 100-3781 mg/dl), and total cholesterol level was 233 +/- 111 mg/dl. High-density lipoprotein was 42.6 +/- 15.4 mg/dl, low-density lipoprotein 110.7 +/- 42.4 mg/dl and very low-density lipoprotein 48 +/- 15 mg/dl. Anti-LPL antibodies were identified in 2 patients (4.5%), both of whom had a family history of dyslipidemia, coronary insufficiency and acute myocardial infarction; one had undergone myocardial revascularization and percutaneous transluminal coronary angioplasty, and both were using fibrates and had normal triglyceride levels. Conclusions: Our findings demonstrate a correlation between the immune response and dyslipoproteinemia in hypertriglyceridemic patients, suggesting that autoimmune disease contributes to the dyslipidemia process.
Palavras-chave
lipoprotein lipase, anti-lipoprotein lipase, atherosclerosis, hypertriglyceridemia, dyslipidemia
Referências
  1. KORN ED, 1955, J BIOL CHEM, V215, P1
  2. SIEDEL J, 1983, CLIN CHEM, V29, P1075
  3. Yadav D, 2003, J CLIN GASTROENTEROL, V36, P54, DOI 10.1097/00004836-200301000-00016
  4. FOSSATI P, 1982, CLIN CHEM, V28, P2077
  5. BABIRAK SP, 1989, ARTERIOSCLEROSIS, V9, P326
  6. BEAUMONT JL, 1977, ATHEROSCLEROSIS, V26, P67, DOI 10.1016/0021-9150(77)90141-1
  7. BEAUMONT J-L, 1970, Revue Europeenne d'Etudes Cliniques et Biologiques, V15, P1037
  8. CARVALHO JF, 2009, REV BRAS REUMATOL, V49, P670
  9. DECARVALHO B, 2004, ARTHRITIS RHEUM, V50, P3610
  10. de Carvalho JF, 2009, CLIN DEV IMMUNOL, DOI 10.1155/2009/803409
  11. de Souza AWS, 2007, LUPUS, V16, P782, DOI 10.1177/0961203307081847
  12. FRIEDEWA.WT, 1972, CLIN CHEM, V18, P499
  13. GLUECK CJ, 1969, AM J MED, V47, P318, DOI 10.1016/0002-9343(69)90158-2
  14. KIHARA S, 1989, NEW ENGL J MED, V320, P1255, DOI 10.1056/NEJM198905113201906
  15. Kodera M, 2005, J RHEUMATOL, V32, P629
  16. Okamoto Y, 1995, J Atheroscler Thromb, V2, P66
  17. PAUCIULLO P, 1986, J ENDOCRINOL INVEST, V9, P517
  18. Pruneta V, 1997, J CLIN ENDOCR METAB, V82, P791, DOI 10.1210/jc.82.3.791
  19. Pruneta-Deloche V, 2005, J CLIN ENDOCR METAB, V90, P3995, DOI 10.1210/jc.2005.0205
  20. Reichlin M, 2002, ARTHRITIS RHEUM, V46, P2957, DOI 10.1002/art.10624
  21. WARNICK GR, 1979, CLIN CHEM, V25, P596
  22. Yoshimura T, 1998, EUR J OBSTET GYN R B, V76, P49, DOI 10.1016/S0301-2115(97)00154-1